Peter Wirth
Chairman of the Board
Former EVP, Legal and Corporate Development, Genzyme
Peter Wirth
Chairman of the Board
Former EVP, Legal and Corporate Development, Genzyme
Peter Wirth is an industry veteran with a track record of value creation in biotechnology. Mr. Wirth was a senior executive at Genzyme from 1996 until its acquisition by Sanofi in 2011, most recently serving as Executive Vice President, Legal and Corporate Development, Chief Risk Officer and Corporate Secretary. During his time at Genzyme, Mr. Wirth had senior management responsibility for the company’s legal function, corporate development function, molecular oncology division, polymer drug discovery and development division and enterprise risk management function. He was instrumental in helping build Genzyme from a small start-up to a diversified, multi-billion dollar enterprise with more than 12,000 employees in locations spanning the globe. Prior to Genzyme, Mr. Wirth practiced law at Palmer & Dodge LLP, where he was head of the firm’s biotechnology practice group and served as outside counsel for Genzyme as well as numerous other biopharmaceutical companies. He is a Director at Zai Lab Limited, a Shanghai-based biopharmaceutical company. Mr. Wirth was a 2012 Advanced Leadership Fellow at Harvard University. He received his B.A. from the University of Wisconsin-Madison and his J.D. from Harvard Law School.
Marsha H. Fanucci
Former Chief Financial Officer, Millennium Pharmaceuticals
View BioMarsha H. Fanucci
Former Chief Financial Officer, Millennium Pharmaceuticals
Marsha H. Fanucci is has served in a number of executive leadership positions at Millennium Pharmaceuticals from 2000 to 2009, including Chief Financial Officer and Senior Vice President of Strategy, Vice President of Finance and Strategy, and Vice President of Corporate Development and Strategy. During her tenure, Ms. Fanucci directly contributed to a series of strategic processes, advanced Millennium to profitability and was instrumental in the acquisition by Takeda Pharmaceutical Company in 2008 for $8.8 billion. Previously, Ms. Fanucci was Vice President of Corporate Development and Strategy at Genzyme Corp. and Vice President and Director at Arthur D. Little. Ms. Fanucci serves on the boards of directors of several biotech companies, including Alnylam Pharmaceuticals, FORMA Therapeutics, Ironwood Pharmaceuticals and Momenta Pharmaceuticals, and non- profit organization The Schwartz Center for Compassionate Care. Ms. Fanucci received a B.S. in pharmacy from West Virginia University Medical School and an M.B.A. from Northeastern University.
Nancy Simonian, M.D.
Former President and Chief Executive Officer, Syros
View BioNancy Simonian, M.D.
Former President and Chief Executive Officer, Syros
Nancy has an established track record of value creation in biotechnology. Nancy is the founding CEO of Syros and served as President and CEO through December 2023. Prior to Syros, she was Chief Medical Officer at Millennium Pharmaceuticals and, previously, Vice President of Clinical Development at Biogen. Nancy has overseen the development of the numerous medicines including AVONEX, TYSABRI, VELCADE, ENTYVIO as well as multiple drugs currently in development in oncology. Under Nancy's leadership at Millennium, VELCADE became a mainstay of treatment for multiple myeloma and a billion-dollar commercial blockbuster. Nancy also built and advanced Millennium's promising pipeline of clinical-stage investigational medicines for cancer and inflammatory diseases. Nancy started her career as a member of the faculty at Harvard Medical School and neurology staff at Massachusetts General Hospital (MGH). She trained in neurology and internal medicine at the MGH and graduated with a bachelor's degree in biology from Princeton. She is currently a member of the board of directors of Seattle Genetics, Alltrna, the Biotechnology Innovation Organization (BIO), and the Damon Runyon Cancer Research Foundation.